CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
London, England, United Kingdom and 72 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
London, United Kingdom and 210 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
London, United Kingdom and 124 other locations
with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...
Phase 3
London, United Kingdom and 263 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
London, United Kingdom and 52 other locations
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer...
Phase 2
London, London, City of, England and 64 other locations
with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NS...
Phase 1, Phase 2
London, United Kingdom and 90 other locations
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on bli...
Phase 3
London, United Kingdom and 207 other locations
The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by inves...
Phase 2
London, United Kingdom and 80 other locations
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Su ...
Phase 2
London, United Kingdom and 88 other locations
Clinical trials
Research sites
Resources
Legal